In a report released on April 12, Thomas Smith from SVB Securities reiterated a Buy rating on Connect Biopharma Holdings (CNTB – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $1.13.
Smith covers the Healthcare sector, focusing on stocks such as Celldex, Intercept Pharma, and Immunic. According to TipRanks, Smith has an average return of 27.2% and a 41.99% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Connect Biopharma Holdings with a $7.00 average price target.
See the top stocks recommended by analysts >>
CNTB market cap is currently $61.65M and has a P/E ratio of -0.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307, CBP-174, and CBP-233.
Read More on CNTB:
